Procalcitonin as a Marker for the Length of Antibiotic Treatment in Peritonitis and Intra-abdominal Infections

Etude Prospective Sur l'Impact de l'Utilisation de la Procalcitonine Dans l'évaluation de la Poursuite ou de l'arrêt du Traitement Antibiotique Empirique Lors de péritonites et d'Infections Intra-abdominales

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01155739

Enrollment

162

Registered

2010-07-02

Start date

2009-06-30

Completion date

2014-06-30

Last updated

2014-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary or Tertiary Peritonitis

Brief summary

Procalcitonin level used for determining length of antibiotic treatment in peritonitis and intra-abdominal infections. Hypothesis is that length of antibiotic use can be shortened by this method.

Detailed description

Prospective randomized trial

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* More than 18 yo * Patient requiring surgery for peritonitis or intra-abdominal infection following: perforation, necrosis, previous operation... * Mannheim Peritonitis score \> 14 * SIRS present * Probability of survival \> 72h * Informed consent by patient/relatives

Exclusion criteria

* No SIRS * Long date corticoid treatment * Immunosuppression * Thyroid medullary carcinoma * Anaphylactic shock * Acute hepatic deficiency

Design outcomes

Primary

Measure	Time frame
antibiotic treatment length, hospitalisation length without antibiotic, infection recurrence, antibiotic cost	at one month and during hospital stay

Countries

Switzerland

Outcome results